What are the different peritoneal dialysis (PD) solutions, their concentrations, indications, and side effects?

Peritoneal Dialysis Solutions: Types, Concentrations, Indications, and Side Effects

Overview of PD Solution Categories

Peritoneal dialysis solutions are categorized by their osmotic agent and buffer system, with glucose-based solutions remaining the primary option despite known membrane toxicity concerns. The main types include glucose-based solutions (in varying concentrations), icodextrin-based solutions, and amino acid-based solutions 1.

---

1. Glucose-Based Solutions

Concentrations Available:

• 1.5% (1.36%) dextrose - Low osmotic strength
• 2.5% (2.27%) dextrose - Medium osmotic strength
• 4.25% (3.86%) dextrose - High osmotic strength

Indications by Concentration:

Low concentration (1.5%):

• Patients with adequate ultrafiltration
• Maintenance of euvolemia without aggressive fluid removal
• Patients with high peritoneal transport characteristics

Medium concentration (2.5%):

• Standard maintenance dialysis
• Moderate ultrafiltration needs
• Most commonly used for routine exchanges

High concentration (4.25%):

• Volume overload requiring aggressive ultrafiltration
• Patients with ultrafiltration failure
• Used for peritoneal equilibration testing (PET) when ultrafiltration failure is suspected 2

Side Effects and Concerns:

Membrane-related toxicity:

• Peritoneal membrane damage with chronic exposure 1
• Increased peritoneal neovascularization and fibrosis 3
• Progressive loss of ultrafiltration capacity over time
• Formation of glucose degradation products (GDPs) and advanced glycation end-products (AGEs) that damage the peritoneum 4

Metabolic effects:

• Systemic glucose absorption leading to hyperglycemia
• Weight gain and obesity
• Dyslipidemia
• Appetite suppression with hypertonic solutions 5
• Protein-sparing effect (beneficial) but metabolic abnormalities (detrimental)

Clinical pitfall: Consistent use of hypertonic glucose solutions accelerates peritoneal membrane deterioration 1. Avoid long-duration dwells with high glucose concentrations whenever possible.

---

2. Icodextrin-Based Solution (7.5%)

Indications:

Icodextrin is specifically indicated for long-duration dwells (>8 hours) where sustained ultrafiltration is needed:

• Long nocturnal dwell in CAPD patients
• Long daytime dwell in APD patients
• Patients with high peritoneal transport characteristics who have poor ultrafiltration with glucose
• Volume overload management 1

Mechanism:

• Glucose polymer providing sustained ultrafiltration over 12-16 hours
• Iso-osmolar solution (does not rely on hyperosmolality)
• Minimal systemic absorption compared to glucose

Benefits:

• Randomized controlled trials demonstrated increased peritoneal ultrafiltration and decreased extracellular fluid volume 1
• Reduced glucose exposure and metabolic complications
• Sustained ultrafiltration throughout long dwells without fluid reabsorption 6
• May reduce peritoneal membrane alterations from glucose toxicity 4

Side Effects:

• Sterile peritonitis (rare, related to maltose metabolites)
• Skin rash (hypersensitivity reactions)
• Interference with certain glucose monitoring systems (falsely elevated readings with glucose dehydrogenase-based meters)
• Higher cost limiting accessibility 7

Clinical note: With icodextrin in place for long dwells, there is no need to drain the dwell early to optimize ultrafiltration 1.

---

3. Amino Acid-Based Solution (1.1%)

Indications:

Specifically indicated for malnourished peritoneal dialysis patients:

• Documented protein-energy malnutrition
• Low serum albumin
• Inadequate dietary protein intake
• Typically used for one exchange daily (not all exchanges) 5, 4

Mechanism:

• Amino acids replace glucose as osmotic agent
• Absorbed amino acids provide nutritional benefit (approximately 15-20g protein equivalent per exchange)
• Lower glucose exposure

Benefits:

• Multiple studies demonstrate nutritional benefit in malnourished PD patients 5
• Protein-sparing effect
• May prevent peritoneal membrane alterations from glucose and acidity 6
• Weight and muscle mass gain in malnourished patients 5

Side Effects:

• Metabolic acidosis (amino acid metabolism generates acid)
• Elevated blood urea nitrogen (BUN)
• Hyperkalemia
• Less ultrafiltration compared to glucose solutions
• Not suitable for volume-overloaded patients
• Higher cost 4

Clinical pitfall: Do not use amino acid solutions in patients with severe metabolic acidosis or hyperkalemia. Limit to one exchange daily to minimize acid load.

---

4. Buffer Systems

Lactate-Buffered (Conventional):

• Standard buffer: 35-40 mEq/L lactate
• Solutions with 40 mEq/L (vs 35 mEq/L) lactate promote weight gain and reduce hospitalization in malnourished patients 5
• Side effect: High lactate contributes to glucose-induced neovascularization through pseudohypoxia 3

Bicarbonate/Lactate-Buffered (Biocompatible):

• Physiologic pH (neutral vs acidic conventional solutions)
• Reduced lactate concentration
• Markedly reduced glucose degradation products
• Better preservation of peritoneal membrane 6
• More biocompatible solutions have shown benefits in preserving residual kidney function 7

Limitation: Higher cost limits widespread use despite superior biocompatibility 7.

---

Prescription Algorithm

For standard CAPD/APD patients:

1. Use 1.5-2.5% glucose solutions for most exchanges
2. Reserve 4.25% glucose for volume overload only
3. Use icodextrin for the single long dwell (nocturnal in CAPD, daytime in APD) 1

For malnourished patients:

• Replace one glucose exchange with amino acid solution daily 5, 4

For volume overload:

• Optimize with icodextrin for long dwell first
• Add 4.25% glucose exchanges only if needed
• Consider dietary sodium restriction and loop diuretics if residual kidney function present 1
• Avoid chronic use of multiple hypertonic exchanges

For high transporters with ultrafiltration failure:

• Icodextrin for long dwells is essential
• Shorten dwell times or use APD without long day dwell
• May need to leave patient "dry" for portion of day 1

---

Critical Considerations

The evidence shows that while newer biocompatible solutions (low GDP, neutral pH, bicarbonate-buffered) demonstrate membrane preservation in short-term studies, large-scale randomized trials examining patient survival, technique survival, and cardiovascular outcomes are lacking 1, 7, 8. However, their widespread acceptance and documented benefits in fluid management and residual kidney function preservation justify their use when accessible 1, 6.

Peritoneal transport characteristics should be assessed at baseline using standardized PET, but routine repeat testing is not necessary unless clinical status changes (decreased drain volumes, ultrafiltration failure, or post-peritonitis) 2.